Key Points The weight loss drug market has reached an important turning point. Eli Lilly is the leader in this market, but faces strong competition from Novo Nordisk. 10 stocks we like better than Eli Lilly › Over time, Eli Lilly (NYSE:LLY) has built a solid portfolio of drugs across treatment areas, and that has resulted in earnings growth. But in recent years, one particular type of drug has supercharged revenue. This market is heading toward a value of almost $100 billion by 2030. I'm talking about the area of weight loss drugs, and particularly in the GLP-1 category. Lilly makes tirzepatide, which is sold for type 2 diabetes under the name Mounjaro and for weight loss under the name Zepbound.Both are injectable products.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.